explore -WSS

explore

author：focus 2025-09-01 15:19:53 - browse：2

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Pregnant women don't need prenatal multivitamins, study concludes

WSS

Change Healthcare cyberattack outage could last weeks

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Obesity now affects over 1 billion people worldwide, study finds

AstraZeneca loses challenge to Medicare drug price negotiation

FDA does about

Families look for replacement for GSK asthma drug Flovent

focus

explore

focus

Hepatitis C has a cure — but many Americans still lack access to it

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Trump demands the U.S. pay no more for drugs than other countries … again

IVF doctors demand details after CooperSurgical lawsuit

Tori Bowie and the unacceptable rates of Black maternal death

Medicare drug price negotiation continues, as pharma counteroffers

Cancer drug shortages should be causing more outrage

Immune cells and nerve overgrowth may explain recurring UTI pain

Continuity nursing helped my family in our darkest PICU moments

Obesity now affects over 1 billion people worldwide, study finds

hotspot

Readout Newsletter: BridgeBio, Akero, and human embryo models

Harvard's David Sinclair gets blowback over aging

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

In search for therapies for solid tumors, companies turn to claudin

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medicare drug price negotiation hearing pits pharma v Biden admin

focus

entertainment

hotspot

focus